Access to Mammography Is Still a Problem

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 6
Volume 4
Issue 6

WASHINGTON--The number of women over age 40 who have ever had a mammography has risen significantly in the past few decades, P. Ellen Parsons, MPH, PhD, said at the spring meeting of the National Mammography Quality Assurance Advisory Committee.

WASHINGTON--The number of women over age 40 who have ever hada mammography has risen significantly in the past few decades,P. Ellen Parsons, MPH, PhD, said at the spring meeting of theNational Mammography Quality Assurance Advisory Committee.

The figures still need improvement, however, and improving accessto mammography remains an important issue. According to the 1992CDC Health Interview Survey, 69% of white women over 40 and 58%of black women over 40 had ever had a mammogram, and of all womenaged 50 to 64, only half had had a mammogram in the past year,she said.

Dr. Parsons is a survey statistician in the Division of HealthInterview Statistics at the National Center for Health Statistics,Centers for Disease Control and Prevention.

As might be expected, women with private health insurance aremore likely to seek mammography than those on Medicare/Medicaid,or with no health insurance, she said. Because they have betteraccess to routine screening programs, women who belong to an HMOobtain mammograms more frequently than women in fee-for-serviceplans.

Dr. Parsons described four major areas that influence access tocare:

Characteristics of the health-care delivery system, includingthe number and type of hospitals and physicians in a given geographicalarea and the time it takes people to reach a delivery site.

Characteristics of the population at risk, such as age, sex, race,cultural background, education, and socioeconomic status.

Utilization of health services, including the stage of healthor illness at which people enter the system, the type of servicesthey receive, and where those services are performed, ie, communityhospital or tertiary care facility.

Consumer satisfaction with convenience, courtesy, cost, qualityof care, and the way test results are provided.

Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.